Back

Baseline early diastolic mitral annular velocities and cancer therapy related cardiac dysfunction in HER2 therapy

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Adib Chowdhury

Victorian Heart Hospital, Clayton (Australia)

6 More presentations in this session

Presentation thumbnail
Incremental value of TAPSE added to HFA-ICOS for ESC-Defined Cancer Therapy–Related Cardiac Dysfunction
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence and severity of cancer-therapy-related cardiac dysfunction during contemporary breast cancer therapy in a real-world cohort
Doctor V. Vinje (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
Machine learning-driven probability of cancer therapy–related cardiac dysfunction in patients with non-Hodgkin lymphoma
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Agreement between manual and AI-enhanced echocardiographic assessment of cancer therapy-related cardiac dysfunction in patients with early breast cancer
Mr E. Orstad (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
Cardiopulmonary fitness and cancer therapy-related cardiac dysfunction defined by CMR: insights from the EMBRACE-MRI study
Doctor T. Goncalves (Toronto, CA)
Abstract Slides Video

Access the full session

Session thumbnail
Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Artificial intelligence–enabled electrocardiography as a pre-treatment predictor of chemotherapy-related cardiac dysfunction
30 August 2026
thumbnail
Congress Presentation
Refining arrhythmic risk stratification in hypertrophic cardiomyopathy through left atrial volume and strain
28 August 2026
thumbnail
Congress Presentation
Echocardiographic variables may improve baseline risk prediction of cancer therapy related cardiac dysfunction
1 September 2024
thumbnail
Congress Presentation
Long-term cardiovascular outcomes after anthracycline and trastuzumab therapy in HER2-positive breast cancer: 5-year follow-up from the EMBRACE-MRI study
30 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources